Document Type
Article
Abstract
Nanoparticles (NPs) constitute a powerful therapeutic platform with exciting prospects as potential inhibitors of amyloid-β (Aβ) aggregation, a process associated with Alzheimer's disease (AD). Researchers have synthesized and tested a large collection of NPs with disparate sizes, shapes, electrostatic properties and surface ligands that evoke a variety of responses on Aβ aggregation. In spite of a decade of research on the NP-Aβ system and many promising experimental results, NPs have failed to progress to any level of clinical trials for AD. A theoretical framework with which to approach this physical system is presented featuring two simple metrics, (1) the extent to which NPs adsorb Aβ, and (2) the degree to which interaction with a NP alters Aβ conformation relative to aggregation propensity. Most of our current understanding of these two interactions has been gained through experimentation, and many of these studies are reviewed herein. We also provide a potential roadmap for studies that we believe could produce viable NPs as an effective AD therapeutic platform.
Digital Object Identifier (DOI)
Publication Info
Published in Physical Biology, Volume 16, Issue 2, 2019.
Rights
© 2019 IOP Publishing Ltd Original content from this work may be used under the terms of the Creative Commons Attribution 3.0 licence. Any further distribution of this work must maintain attribution to the author(s) and the title of the work, journal citation and DOI.
APA Citation
van, Moss, M. A., & Uline, M. J. (2019). Obstacles to translating the promise of nanoparticles into viable amyloid disease therapeutics. Physical Biology, 16(2), 021002.https://doi.org/10.1088/1478-3975/aafc66